BCM
CHRS icon

Bridgeway Capital Management’s Coherus Oncology CHRS Stock Holding History

Bridgeway Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$745K Hold
441,000
– – 0.02% 758
2025
Q4 		$626K Buy
441,000
+186,000
+73% +$271K 0.01% 782
2025
Q3 		$418K Buy
255,000
+112,000
+78% +$125K 0.01% 840
2025
Q2 		$105K Hold
143,000
– – ﹤0.01% 1065
2025
Q1 		$115K Sell
143,000
-60,000
-30% -$69.1K ﹤0.01% 1010
2024
Q4 		$280K Sell
203,000
-109,700
-35% -$123K 0.01% 939
2024
Q3 		$325K Buy
312,700
+69,700
+29% +$95.6K 0.01% 962
2024
Q2 		$420K Buy
+243,000
New +$489K 0.01% 896

Other funds holding CHRS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return